U.S. FDA approves Cangene's anti-hepatitis B product

01-Feb-2006

Cangene announced that the U.S. food and Drug Administration (FDA) has approved Cangene's HepaGam B(TM) for treatment following acute exposure to hepatitis B virus. HepaGam B(TM) is Cangene's hepatitis B immune globulin (human), a purified antibody or hyperimmune that is specific for the hepatitis B virus.

Cangene manufactures HepaGam B(TM) in its Winnipeg facility using a process similar to that of WinRho(R) SDF and Vaccinia immune globulin, the Company's earlier FDA-approved drugs. The Company anticipates that the drug will be distributed in the U.S. by Apotex Corp., a member of the Apotex Group, Cangene's majority shareholder. The companies expect to launch the product within the next few months.

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...